(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment ...

AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

Results from the Phase III TEMPLE trial show that patients administered Qulipta (atogepant) experienced significantly fewer ...

US pharma major AbbVie (NYSE: ABBV) today announced positive top-line results from its Phase III TEMPLE multicenter, ...

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of significantly improving the ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

Two Democratic lawmakers have renewed accusations that large pharma companies have evaded paying U.S. taxes through a ...

From migraine to Parkinson’s and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ...

This was the stock's third consecutive day of losses.

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage ...